Liu SV, et al. - Researchers report the outcomes of atezolizumab (an anti-programmed death ligand-1 [PD-L1] antibody) plus chemotherapy in patients with advanced, treatment-naïve non-small-cell lung cancer (NSCLC). Treatment regimen was atezolizumab plus carboplatin with paclitaxel (Arm C: atezo/cb/pac), pemetrexed (Arm D: atezo/cb/pem, maintenance pemetrexed permitted), or nab-paclitaxel (Arm E: atezo/cb/nab-pac), four–six cycles, then atezolizumab maintenance. Findings demonstrated good tolerability as well as hopeful effectiveness of atezolizumab with chemotherapy, with median progression-free survival ranging from 5.7 to 8.4 months and overall survival ranging from 12.9 to 18.9 months.